Autopsy report · NCT02007252
ACZ885 for the Treatment of Abdominal Aortic Aneurysm
Cause of deathFutility
“The results of a third interim analysis (ad hoc) indicated a lack of efficacy and futility in continuing the trial.”
Life of this trial
- Ran for about 1 year 10 months before it stopped.
- 65 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Abdominal Aortic Aneurysm (AAA)
- Interventions
- ACZ885; Placebo
- Participants
- 65
- Sites
- 9
- Countries
- Denmark, Netherlands, Sweden, United Kingdom, United States
Trials that died the same way
- LBH589 in Refractory Myelodysplastic Syndromes (MDS)
“Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.” - A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
“Lack of efficacy determined at interim analysis” - Effectiveness of Periocular Drug Injection in CATaract Surgery
“Results of interim analysis: stop the trial due to one group being significantly different from the other three groups. Furthermore, shortage of study medication.” - Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
“The study was terminated based on the results of a planned interim analysis that showed futility of efficacy.” - Hydroxyurea in Primary Progressive Multiple Sclerosis
“No efficacy (interim.analysis)”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.